Managers
NorthEdge-backed Accrol Group Holdings has revealed plans to to float on the AIM market of the London Stock Exchange. Dealings are expected to commence on AIM on 10 June 2016.
Established in 1993 by the Hussain family, Accrol has grown to become a leading supplier of tissue products, supplying both the premium retail and UK discount markets. Accrol has a 35 per cent market share of the discount market and seven per cent. of the overall UK tissue market. The business manufactures a wide range of household and away from home tissue products for a number of blue-chip retailers and
ClickDimensions, a provider of marketing automation and email marketing technology, has received a growth equity investment from Accel-KKR, a leading technology-focused private equity firm.
The new partnership will allow ClickDimensions to continue its significant growth while making additional investments in existing products and driving further product innovation in the marketing technology space. Terms of the investment were not disclosed.
The company, with over 2,400 customers and nearly 1,000 reseller partners, delivers value to companies of all sizes through its two platforms, ClickDimensions and Automational. Embedded directly in Microsoft Dynamics CRM, the ClickDimensions solution brings robust marketing tools and a
Investec Bank has arranged the long term refinancing of a portfolio of four UK projects totalling 40MW solar portfolio owned by Canadian Solar Inc (CSIQ). The long term debt was provided by Bayern LB after Investec ran competitive process for Canadian Solar.
Investec originally provided a short term bridging facility that funded the portfolio shortly after its connection to the electricity grid.
Olivier Fricot, head of Power and Infrastructure Lending, Investec, says: “Having supported Canadian Solar in its first ROC based project financing Investec is delighted to have arranged a long term financing solution on very attractive terms to Canadian
Ergomed is acquiring Haemostatix from a group of UK-based VC investors including Albion Ventures, Catapult Ventures, Esperante, as well as Nesta and the Wellcome Trust for an initial consideration of GBP8.0 million, with a contingent consideration of GBP20.0 million.
Nottingham based Haemostatix, a spin-out of the University of Nottingham, is a developer of topical clotting agents. The technology is based on a novel class of molecule that binds directly to fibrinogen to promote haemostasis and is targeted at the global surgical bleeding market, worth more than USD2 billion.
The two lead products developed by the Haemostatix team are PeproStat (Phase
RINA is to acquire the entire share capital of Edif Group Limited (Edif), a portfolio company of Phoenix Equity Partners (Phoenix), for GBP118.5 million (around EUR151 million).
The acquisition represents a further step towards the fulfilment of RINA’s broader growth strategy, which will increase its geographical coverage, and deliver a higher level of technical expertise for its customers. In particular, the acquisition of Edif will significantly increase RINA’s presence in the UK, alongside the US and German market, where the combination of the two groups will provide a platform for further expansion.
Edif is a leading worldwide provider of
Aquila Capital is providing institutional investors with access to its latest diversified renewable energy portfolio – the Aquila Capital Renewables Fund III – via a bond solution.
The securitisation, which already has been given an indicative investment grade rating by an ESMA-recognised rating agency, is targeting an A- rating thanks to the high quality of the underlying portfolio, its efficient structure and very modest structuring costs.
Both the securitisation and a direct investment in the Fund provide investors with access to a conservative, broadly diversified portfolio of wind and photovoltaic plants in politically stable countries in Western Europe. The Fund
Malta has addressed one of the biggest issues in European fund management – the speed to market – with its new Notified Alternative Investment Funds (NAIF) framework, according to Jeremy Leach, Chief Executive Officer of the Managing Partners Group (MPG).
Malta, together with Luxembourg, is one of the first two jurisdictions in Europe to adopt the new framework and the move is likely to expand its share of the alternative investment funds (AIF) market, marking yet another step in the country’s move to becoming a leading financial centre, Jeremy Leach says.
Under the NAIF framework, product providers are directly regulated
Swedish company reconstruction firm FrontOffice Nordic AB, which raised almost EUR600,000 from crowdfunding investors on FundedByMe in February 2016, has been listed on the Nordic Growth Market (NGM) stock exchange.
This makes FrontOffice the first successfully crowdfunded company in Scandinavia, and one of the first in Europe, to be listed on a stock exchange.
Crowdfunding investors into FrontOffice – who could buy shares for a minimum investment of EUR53 – are now able to trade those shares on this regulated stock exchange, licensed by the Financial Supervisory Authority.
“With the rate of market maturation, this is very exciting for FundedByMe
American International Group (AIG) has launched a new insurance product developed specifically to protect investors on equity crowdfunding platforms against issuer fraud.
Crowdfunding platforms enable innovators to bring their ideas to life and also give retail investors the opportunity to provide capital for start-ups and growth stage companies around the world. Historically, only high net worth individuals and institutional investors such as venture capital funds and private equity firms were offered these opportunities.
“As a sector still in its infancy, equity crowdfunding platforms are only as strong as the confidence they instil in their investors,” says Lex Baugh, President of
IK Investment Partners’ IK VII Fund is to acquire a majority stake in Marle International SAS (Marle), an independent implant contract manufacturing company in Europe, from The Carlyle Group.
Carlyle’s Europe Technology fund, majority shareholder since 2009, will reinvest alongside management and the Marle family. Financial terms of the transaction have not been disclosed, and completion of the transaction is subject to legal and regulatory approvals.
Established over 30 years ago as a family business, Marle has become a major company in the orthopaedic industry. The Company provides specialised manufacturing services for the production of a wide range of hip,
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
